Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 25.58B P/E 35.29 EPS this Y - Ern Qtrly Grth 7.50%
Income 4.87B Forward P/E 0.57 EPS next Y - 50D Avg Chg -3.00%
Sales 25B PEG - EPS past 5Y - 200D Avg Chg -2.00%
Dividend 164.00% Price/Book 3.62 EPS next 5Y - 52W High Chg -19.00%
Recommedations - Quick Ratio 0.33 Shares Outstanding 2.25B 52W Low Chg 25.00%
Insider Own - ROA 10.29% Shares Float 141.83M Beta 0.30
Inst Own 0.02% ROE 46.30% Shares Shorted/Prior -/- Price 12.00
Gross Margin 66.74% Profit Margin 19.47% Avg. Volume 40,811 Target Price -
Oper. Margin 27.60% Earnings Date May 7 Volume 29,176 Change -1.64%
About COLOPLAST SPON ADS EACH REPR 0.

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

COLOPLAST SPON ADS EACH REPR 0. News
02/09/24 Coloplast A/S - Allocation of Share Options
02/09/24 Coloplast launches Peristeen® Light for people with bowel disorders
02/09/24 Coloplast A/S - Interim Financial Report, Q1 2023/24
01/31/24 Coloplast launches Biatain® Silicone Fit for pressure injury prevention and wound management in the US
01/19/24 Coloplast A/S - Q1 2023/24 Earnings Release - Invitation for conference call on 9 February 2024 at 11.00am CET
12/07/23 Coloplast A/S - Change of auditor
12/07/23 Coloplast A/S - Articles of Association
12/07/23 Coloplast A/S - Decisions at the Annual General Meeting 2023
12/07/23 Coloplast A/S's Dividend Analysis
11/14/23 Coloplast A/S - Notice of Annual General Meeting 2023
11/09/23 Coloplast announces new manufacturing site in Portugal
11/09/23 Coloplast A/S - Annual Report 2022/23 & Remuneration Report 2022/23
11/09/23 Coloplast A/S - Full-Year Financial Results 2022/23
11/09/23 Coloplast A/S - FY 2023/24 Financial Guidance
09/12/23 Coloplast A/S - Financial Calendar 2023-24
09/01/23 Coloplast A/S - Coloplast completes the acquisition of Kerecis - Invitation for conference call on Monday, 4 September 2023 at 14.00-15.00 CEST
09/01/23 Coloplast A/S - Announcement no. 08/2023 - Coloplast announces registration of share capital increase of 12.2 new B shares completed
08/31/23 Coloplast completes the acquisition of Kerecis
08/29/23 Coloplast A/S - Announcement no. 07/2023 – Coloplast announces completion of offering of 12.2 million new B shares
08/29/23 Coloplast A/S - Announcement no. 06/2023 – Coloplast launches offering to raise around DKK 9 billion through issue of new B shares in a directed issue and private placement